ALIMTA receives positive opinion from CHMP
26 September 2011 | By Eli Lilly and Company
CHMP has issued a positive opinion for the use of ALIMTA® as continuation maintenance therapy for deadly form of lung cancer...
List view / Grid view
News
AstraZeneca announces first approval of FASLODEX™ (fulvestrant) in Japan
26 September 2011 | By AstraZeneca
AstraZeneca announced that FASLODEX™ (fulvestrant) has received regulatory approval...
Roche’s investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer
25 September 2011 | By Roche
Phase II study TDM4450g results announced...
KOMBOGLYZE™ receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
23 September 2011 | By AstraZeneca
KOMBOGLYZE™ receives a positive opinion from CHMP...
Novartis gains positive CHMP opinion for Rasitrio®
23 September 2011 | By Novartis
The CHMP adopted a positive opinion for Rasitrio® for the treatment of high blood pressure...
Novartis drug Afinitor® effective in patients with non-cancerous kidney tumors associated with TSC in Phase III trial
23 September 2011 | By Novartis
A Phase III study of Afinitor® (everolimus) tablets* met its primary endpoint of best overall angiomyolipoma response rate...
European CHMP adopts positive opinion for Eviplera(R)
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
Positive opinion on the usage of Levemir® (insulin detemir) as add-on therapy to Victoza® (liraglutide) in people with type 2 diabetes
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir®...
Positive opinion on the use of Levemir® (insulin detemir) in children with type 1 diabetes aged two to five years
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir...
New study shows investigational BIBF 1120 demonstrated positive trend in reducing lung function loss in Idiopathic Pulmonary Fibrosis
22 September 2011 | By Boehringer Ingelheim
Phase II clinical trial results...
Sygnature Chemical Services becomes Sygnature Discovery
21 September 2011 | By Sygnature Discovery Limited
Sygnature Chemical Services, has become Sygnature Discovery to better reflect its Integrated Drug Discovery Service-Offering...
Viramune® (nevirapine) prolonged-release once-daily formulation receives approval in the EU
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
Sanofi Pasteur acquires exclusive, worldwide license for acne vaccine and treatment
21 September 2011 | By Sanofi Pasteur
The pre-clinical vaccine was developed by researchers at the University of California...
Lilly steps up efforts to improve diversity in clinical trials
20 September 2011 | By Eli Lilly and Company
Observational study leads to systemic approach to improve minority enrollment...
Bristol-Myers Squibb and Ono enter into strategic agreement
20 September 2011 | By Bristol-Myers Squibb
Strategic agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)...
